Want to see GB:POLB full AI Analyst Report?
POLB Stock Chart & Stats
3.55 p
0.24 p(5.04%)
At close: 4:00 PM EST
3.55 p
0.24 p(5.04%)
Day’s Range― - ―
52-Week Range2.50 p - 9.00 p
Previous CloseN/A
Volume846.29K
Average Volume (3M)1.12M
Market Cap
£47.33M
Enterprise Value20.18 p
Total Cash (Recent Filing)£7.71M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Sep 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding763,437,130
10 Day Avg. Volume836,211
30 Day Avg. Volume1,116,415
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.80
Price to Sales (P/S)0.00
P/FCF Ratio-4.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Early Clinical Target EngagementRobust, dose‑dependent cytokine suppression in a controlled human LPS challenge demonstrates clear target engagement and biological activity. This durable mechanistic signal de‑risks early development, strengthens translational rationale, supports dose selection, and improves partner and investor confidence over the coming development cycle.
Regulatory & Intellectual Property ProtectionOrphan Drug designation plus broad patents extending to 2044 provide meaningful exclusivity and commercial protection if approved. These structural rights support pricing power, reduce competitive erosion, and materially increase attractiveness to partners and payers across the long term.
Capital Access And Low LeverageRecent successful fundraising and a sizeable grant, combined with a positive cash balance, demonstrate the company can access non‑dilutive and dilutive funding. Coupled with no reported debt, this gives short‑to‑midterm runway to deliver key readouts and pursue partnerships, preserving optionality for further value creation.
Bears Say
Pre‑revenue Operating LossesWith zero product revenue and recurring multi‑million pound net losses, the business lacks internal cash generation to fund development. This structural absence of operating revenue prolongs dependency on external financing or partnering and compresses the firm’s ability to self‑fund late‑stage trials or commercialization.
Sustained Cash Burn And Limited RunwayOngoing negative operating cash flow and repeated free cash outflows create structural funding pressure. Management cites runway into 2027, meaning further financing or licensing will be required before pivotal stages; that necessity can force dilution or accelerated partnering under suboptimal terms.
Small, Uncontrolled Pivotal Path And Partner DependenceA single‑arm N=30 design limits definitive efficacy claims and will likely require larger controlled studies to secure regulatory approval and payer coverage. Coupled with explicit dependence on external partners for late‑stage development and commercialization, the company’s upside and execution hinge on partner interest and negotiation outcomes.
Poolbeg Pharma Ltd. News
POLB FAQ
What was Poolbeg Pharma Ltd.’s price range in the past 12 months?
Poolbeg Pharma Ltd. lowest share price was 2.50 p and its highest was 9.00 p in the past 12 months.
What is Poolbeg Pharma Ltd.’s market cap?
Poolbeg Pharma Ltd.’s market cap is £47.33M.
When is Poolbeg Pharma Ltd.’s upcoming earnings report date?
Poolbeg Pharma Ltd.’s upcoming earnings report date is Sep 08, 2026 which is in 46 days.
How were Poolbeg Pharma Ltd.’s earnings last quarter?
Poolbeg Pharma Ltd. released its earnings results on Apr 28, 2026. The company reported -0.005 p earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Poolbeg Pharma Ltd. overvalued?
According to Wall Street analysts Poolbeg Pharma Ltd.’s price is currently Overvalued.
Does Poolbeg Pharma Ltd. pay dividends?
Poolbeg Pharma Ltd. does not currently pay dividends.
What is Poolbeg Pharma Ltd.’s EPS estimate?
Poolbeg Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Poolbeg Pharma Ltd. have?
Poolbeg Pharma Ltd. has 763,437,130 shares outstanding.
What happened to Poolbeg Pharma Ltd.’s price movement after its last earnings report?
Poolbeg Pharma Ltd. reported an EPS of -0.005 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.371%.
Which hedge fund is a major shareholder of Poolbeg Pharma Ltd.?
Currently, no hedge funds are holding shares in GB:POLB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Poolbeg Pharma Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Bought Shares
Worth £250.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-44.05%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.98%
Trailing 12-Months
Company Description
Poolbeg Pharma Ltd.
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company based in the United Kingdom, focused on developing treatments for infectious diseases. Its pipeline features several key programs: POLB 001, a p38 MAP Kinase inhibitor intended for severe influenza; POLB 002, a pioneering, in-licensed RNA-based immunotherapy administered intranasally to combat respiratory virus infections; and POLB 003, an intramuscular vaccine aimed at preventing Melioidosis. Beyond specific therapeutic candidates, Poolbeg also holds licensed access to advanced micro- and nanoencapsulation technology for an oral vaccine delivery system designed to stimulate gut immunity. The company further advances its research through an artificial intelligence-powered drug program. Additionally, Poolbeg is developing a biomarker platform to identify individuals at high risk of severe disease, alongside a model-derived vaccine discovery platform to pinpoint novel vaccine candidates. Incorporated in 2021, Poolbeg Pharma plc is headquartered in London.
Technical Analysis
ImmuPharma
―
Sareum Holdings
―
HemoGenyx Pharmaceuticals Plc
―
Open Orphan Plc
―
Aptamer Group Plc
―